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Volume 40, Number 6 Abstracts 1259Effect of long saphenous vein stripping on deep venous reflux
MacKenzie RK, Allan L, Ruckley CV, et al. Eur J Vasc Endovasc Surg
2004;28:104-7.
Conclusion: Stripping of the greater saphenous vein (GSV) abolishes
deep venous reflux in a significant proportion of limbs. Continued GSV
insufficiencymay be associated with development of new deep venous reflux.
Summary: The authors examined the effect of GSV stripping on
known deep venous reflux and development of new deep venous reflux. The
study included 62 consecutive patients who underwent saphenofemoral
junction disconnection, multiple stab avulsions of varicosities, and who may
or may not have undergone successful stripping of the GSV to the knee.
Duplex ultrasound scanning was performed to detect venous reflux preop-
eratively and at a median of 24 months postoperatively. Completely stripped
limbs were defined as those in which complete stripping of the GSV to the
knee was confirmed on postoperative duplex scans. Duplex scanning–
Detected reflux time greater than 0.5 seconds was considered abnormal.
Preoperatively, 42% of limbs had deep venous reflux. Follow-up post-
operative duplex scans indicated that the GSV had been completely stripped
in only 38% of limbs. In patients with preoperative deep venous reflux,
complete stripping was associated with a significant reduction in the preva-
lence of superficial femoral vein reflux (P  .001) and popliteal vein reflux
(P .016). In patients without preoperative deep venous reflux, incomplete
stripping of the GSV was associated at follow-up with development
of superficial femoral vein reflux (P  .031) and popliteal vein reflux
(P  .008).
Comment: The authors; data suggest that successful stripping of a
refluxing GSV may improve reflux in the femoral and popliteal veins.
Incomplete stripping may lead to development of new deep venous reflux in
the femoral and popliteal veins. This study affirms the growing realization
that deep venous reflux may derive from the presence of superficial venous
reflux. The results suggest that patients with a combination of deep and
superficial venous reflux may benefit from stripping of the refluxing GSV
and, in fact, may be harmed by leaving a refluxing GSV in situ.
Aspirin plus clopidogrel compared with clopidogrel alone after recent
ischemic stroke or transient ischemic attack in patients at high risk
patients (MATCH): Randomized double-blind placebo-controlled
trial
Hans-Christoph D, Bogousslavsky J, Brass LM, and the MATCH Investi-
gators. Lancet 2004;364:331-7.
Conclusion: The combination of aspirin and clopidogrel in patients
with recent ischemic stroke or transient ischemic attack (TIA) is associated
with a nonsignificant difference in reducingmajor vascular events, compared
with clopidogrel alone. The risk for life-threatening or major bleeding is,
however, increased with the addition of aspirin to clopidogrel in this patient
group.
Summary: The CAPRIE study (Lancet 1996;348:1329-39) demon-
strated that clopidogrel is superior to aspirin in reducing cardiovascular end
points in patients with previous manifestations of atheroembolic disease.
The clopidogrel benefit was amplified in some subgroups of patients at high
risk. In this study the authors sought to assess whether the combination of
aspirin plus clopidogrel may have greater benefit than clopidogrel alone for
prevention of vascular events in patients with recent ischemic stroke or TIA.
This randomized double-blind placebo-controlled trial compared aspi-
rin, 75 mg/d, with placebo in 7599 patients at high-risk who were already
receiving clopidogrel, 75 mg/d, and who had had a recent ischemic stroke
or TIA and at least 1 additional vascular risk factor. Treatment and follow-up
was 18 months. The primary end point was the composite end point of
ischemic stroke, myocardial infarction, vascular death, or hospitalization
with acute ischemia (TIA, angina, worsening peripheral arterial disease). The
data were analyzed on an intent-to-treat basis, with the log-rank test and
Cox proportional hazards model.
The primary end point was reached in 596 patients (15.7%) receiving
aspirin plus clopidogrel compared with 636 patients (16.7%) receiving
clopidogrel alone (relative risk reduction 6.4%, 95% confidence interval,
4.6 to 16.3; absolute risk reduction 1%, 95% CI 0.6 to 2.7). Life-
threatening bleeding was higher in the group receiving aspirin plus clopi-
dogrel versus clopidogrel alone: 3.6% versus 1.3% (absolute risk increase
1.3%, 95% CI 0.6-1.9). Major bleeding was also increased in the group
receiving aspirin plus clopidogrel, but there were no differences in mortality
compared with group receiving clopidogrel alone.Comment: The CAPRIE study established that clopidogrel is more
effective than aspirin in reducing cardiovascular end points in patients with
vascular disease. This study highlights the old axiom that the enemy of good
may be better. Results do not support the use of clopidogrel plus aspirin in
patients with a recent TIA or stroke. At this time clopidogrel alone appears
to be optimal antiplatelet therapy in these patients.
Temporal gene expression after prosthetic arterial grafting
Willis DJ, Kalish JA, Li C, et al. J Surg Res 2004;120:27-36.
Conclusion: Specific upregulation of genes and specific downregula-
tion of genes occurs in associated with prosthetic grafting in an animal
model.
Summary: Smooth muscle cell proliferation and matrix production
associated with intimal hyperplasia is well known. The study evaluated
potential upregulation and downregulation of genes after prosthetic arterial
grafting, which by inference may influence intimal hyperplasia. The authors
specifically targeted gene expression at the distal anastomosis of prosthetic
arterial grafts, with micro-ray analysis.
Expandable polytetrafluoroethylene (ePTFE) carotid interposition
grafts (n  12) were implanted into mongrel dogs. Fragments from the
distal anastomosis were harvested at 7, 14, 30, or 60 days. The contralateral
carotid artery served as control. RNA was isolated from anastomotic tissue
and from the paired control arteries. Samples were probed with oligonucle-
otide micro-rays consisting of approximately 10,000 human genes.
A total of 49 genes were found to be upregulated, and 37 genes were
found to be downregulated at various points. Some genes were upregulated
at all time intervals, and included collagen type 11 and type 12, 80 K-L
protein (myristoylated alanine-rich protein C kinase substrate), and os-
teopontin. Eight genes consistently downregulated. These included
smoothelin and tropomyosin.
Comment: There is no consensus regarding the most appropriate
method for analyzing gene expression with micro arrays. Studies such as this
are basically “shotgun approaches” that seek to identify gene expression
associated with a biologic process. They do, however, provide a useful
starting point, and likely will ultimately lead to further studies specifically
linking gene expression with biologic function.
Fondaparinux or enoxaparin for initial treatment of symptomatic deep
venous thrombosis: Randomized trial
Buller HR, Davidson BL, Decousus H, and the Matisse Investigators. Ann
Intern Med 2004;140:867-73.
Conclusion:Once-daily subcutaneous fondaparinux is as effective and
safe as twice-daily body weight–adjusted enoxaparin for initial treatment of
symptomatic deep venous thrombosis (DVT).
Summary: This randomized, double-blind study was conducted in
154 centers worldwide, with 2205 patients with acute symptomatic DVT.
The goal was to establish whether fondaparinux had similar efficacy and
safety as enoxaparin in treatment of acuteDVT. Patients were randomized to
received fondaparinux, 7.5mg (5.0 mg in patients weighing  50 kg and
10.0 mg in patients weighing  100 kg) subcutaneously once daily, or
enoxaparin, 1 mg/kg of body weight, subcutaneously twice daily for at least
5 days, until vitamin K antagonists induced an international normalized ratio
greater than 2.0. The primary efficacy outcome was the 3-month incidence
of symptomatic recurrent venous thromboembolism (VTE). Safety out-
comes were major bleeding during initial treatment, and death. All out-
comes were adjudicated with blinded assessment by an independent com-
mittee.
Of 1098 patients randomly assigned to receive fondaparinux, 43 pa-
tients (3.9%) had a recurrent VTE event, compared with recurrent VTE
events in 45 patients (4.1%) of 1107 patients randomly assigned to receive
enoxaparin (absolute difference, 0.15 percentage point; 95% confidence
interval,1.8 to	1.5 percentage points). Major bleeding occurred in 1.1%
of patients receiving fondaparinux and 1.2% of patients receiving enoxapa-
rin. Mortality rates were 3.8% and 3.0%, respectively.
Comment: Fondaparinux is a synthetic selective inhibitor of factor Xa.
This study indicates the noninferiority of fondaparinux compared with
enoxaparin for treatment of acute DVT. It adds to the growing evidence that
inhibitors of activated factor Xa are safe, effective and easy to use antithrom-
botic agents.
